Home Biotechnology Industry News
Biotechnology industry news, updates, and press releases

Valuation approaches to biotechnology companies by angel investors and venture capitalists often appear to the entrepreneurs to be based on voodoo rather than sound principles of finance. While there may be some truth to that perception, there is actually a very sound, somewhat complex, internal logic to the way private biotechnology companies are valued. Note the emphasis on the word “private.” This article will focus entirely on the valuation methodology of companies that are not yet listed. Moreover, the article will not consider the valuation approaches used by, say, a pharmaceutical company when it is targeting a biotechnology company for acquisition or strategic partnering. The emphasis of this piece is on the thought process or algorithm in play — the so-called “Venture Capital Method” — when an investor is looking at a biotechnology company in the seed stage or in the first or second round of venture capital funding. Full details at the Journal of Commercial Biotechnology

The process of commercializing a new item or service in the U.S. health care market involves three distinct but necessary components: coverage, coding, and reimbursement.  This article provides an overview of these processes and the challenges in successfully navigating the course and spotting the particular issues for individual items and services. Full details at the Journal of Commercial Biotechnology

As surely as the bio-enterprise can benefit from positive media coverage, it cannot thrive in the face of unanswered negative and/or inaccurate media attention. On all counts, the bio-enterprise must be able to strategically engage with the media at every stage in its life cycle. This article describes the global science-business media landscape, including traditional media and emergent social media and information in the online space. Current research is used to document the interdependence of media, how sources of information feed media coverage, the challenges of science communication in the broader context of business, and the effect of media engagement by the CEO.

A strategic model is presented which relates the bio-enterprise to global media, providing a larger framework within which to develop media action plans at critical junctures in the life of the bio-enterprise. Further documented is the difference between journalistic and non-journalistic media, and how journalistic ethics and standards guidelines work with ethical persuasion practices to the benefit of the bio-enterprise. Full details at the Journal of Commercial Biotechnology

The convergence of ubiquitous smartphones, wireless Internet, and low-cost monitoring devices, is driving the emergence of a new world of digital health. At the same time, cost pressures on healthcare are creating demand for new ways to not just improve the way patients receive information and care and the way doctors provide it, but fundamentally change the way they interact with each other. The article discusses a venture capitalist's approach to investing in the sector.


 

Full details at the Journal of Commercial Biotechnology